Last reviewed · How we verify
NUZ-001
At a glance
| Generic name | NUZ-001 |
|---|---|
| Sponsor | Merit E. Cudkowicz, MD |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- HEALEY ALS Platform Trial - Master Protocol (PHASE2, PHASE3)
- HEALEY ALS Platform Trial - Regimen I NUZ-001 (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NUZ-001 CI brief — competitive landscape report
- NUZ-001 updates RSS · CI watch RSS
- Merit E. Cudkowicz, MD portfolio CI